Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extended Prophylaxis Comparing low molecular weight heparin (LMWH) to Aspirin in Total hip arthroplasty.

Next Previous
X
Search
Trial Profile

Extended Prophylaxis Comparing low molecular weight heparin (LMWH) to Aspirin in Total hip arthroplasty.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Dalteparin sodium (Primary) ; Enoxaparin sodium
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EPCAT

    • Most Recent Events

    • 28 Jul 2011 This study was halted prematurely upon advice from the DSMB that the primary study objective for non-inferiority had been met
    • 28 Jul 2011 Results presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
    • 28 Jul 2011 Primary endpoint 'Thromboembolism-event-rate' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top